サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1411694

糖尿病黄斑浮腫治療市場：治療法別、エンドユーザー別-2024-2030年の世界予測

Diabetic Macular Edema Treatment Market by Treatment (Corticosteroid Injections, Drugs, Laser Treatment), End-User (Hospitals, Ophthalmology Clinics) - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 198 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
糖尿病黄斑浮腫治療市場：治療法別、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 198 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

糖尿病黄斑浮腫治療市場規模は2023年に29億7,000万米ドルと推定され、2024年には31億2,000万米ドルに達すると予測され、CAGR 5.11％で2030年には42億2,000万米ドルに達すると予測されます。

糖尿病黄斑浮腫治療の世界市場

主な市場の統計
基準年[2023］ 29億7,000万米ドル
予測年[2024］ 31億2,000万米ドル
予測年【2030年 42億2,000万米ドル
CAGR（%） 5.11%
糖尿病黄斑浮腫治療 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは糖尿病黄斑浮腫治療市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、糖尿病黄斑浮腫治療市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-糖尿病黄斑浮腫治療市場の市場規模および予測は？

2-糖尿病黄斑浮腫治療市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-糖尿病黄斑浮腫治療市場における技術動向と規制の枠組みは？

4-糖尿病黄斑浮腫治療市場における主要ベンダーの市場シェアは？

5-糖尿病黄斑浮腫治療市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 高齢者人口の増加に伴い、世界的に糖尿病有病率が上昇
      • 糖尿病網膜症および糖尿病黄斑浮腫に対する意識の高まり
      • 糖尿病性網膜症に対する意識を高める政府主導の取り組み
    • 抑制要因
      • DME治療の高額な治療費
    • 機会
      • 新しい先進的な治療オプションのイントロダクションの増加
      • DME治療に対する償還ポリシーとヘルスケア保険の改善
    • 課題
      • DME治療の臨床試験設計の課題
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 糖尿病黄斑浮腫治療市場治療別

  • コルチコステロイド注射
  • 薬物
  • レーザー治療
  • 薬物治療

第7章 糖尿病黄斑浮腫治療市場：エンドユーザー別

  • 病院
  • 眼科クリニック

第8章 南北アメリカの糖尿病黄斑浮腫治療市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域の糖尿病黄斑浮腫治療市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカの糖尿病黄斑浮腫治療市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第12章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • AbbVie Inc.
    • Adverum Biotechnologies
    • Aerpio Pharmaceuticals
    • Alcon Vision LLC
    • Alimera Sciences, Inc.
    • Arctic Vision
    • Bausch & Lomb Incorporated
    • Chugai Pharmaceutical Co., Ltd.
    • EyePoint Pharmaceuticals Inc. .
    • F. Hoffmann-La Roche Ltd.
    • Genentech, Inc.
    • GlaxoSmithKline PLC
    • Graybug Vision, Inc.
    • KalVista Pharmaceuticals, Inc.
    • Kodiak Sciences Inc
    • Kubota Pharmaceutical Holdings Co. Ltd.
    • Novartis AG
    • Ocugen Inc.
    • Oculis Holding AG
    • Ocuphire Pharma, Inc.
    • Oxurion NV
    • Pfizer Inc.
    • Regeneron Pharmaceuticals Inc
    • Teva Pharmaceutical Industries Ltd.
    • YD Life Science
  • 主要な製品ポートフォリオ

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. DIABETIC MACULAR EDEMA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. DIABETIC MACULAR EDEMA TREATMENT MARKET DYNAMICS
  • FIGURE 7. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 8. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 10. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. DIABETIC MACULAR EDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. DIABETIC MACULAR EDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. DIABETIC MACULAR EDEMA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 6. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 11. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. DIABETIC MACULAR EDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 100. DIABETIC MACULAR EDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 101. DIABETIC MACULAR EDEMA TREATMENT MARKET LICENSE & PRICING
目次
Product Code: MRR-2A0283E256C1

[198 Pages Report] The Diabetic Macular Edema Treatment Market size was estimated at USD 2.97 billion in 2023 and expected to reach USD 3.12 billion in 2024, at a CAGR 5.11% to reach USD 4.22 billion by 2030.

Global Diabetic Macular Edema Treatment Market

KEY MARKET STATISTICS
Base Year [2023] USD 2.97 billion
Estimated Year [2024] USD 3.12 billion
Forecast Year [2030] USD 4.22 billion
CAGR (%) 5.11%
Diabetic Macular Edema Treatment Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Diabetic Macular Edema Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Diabetic Macular Edema Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Diabetic Macular Edema Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adverum Biotechnologies, Aerpio Pharmaceuticals, Alcon Vision LLC, Alimera Sciences, Inc., Arctic Vision, Bausch & Lomb Incorporated, Chugai Pharmaceutical Co., Ltd., EyePoint Pharmaceuticals Inc. ., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline PLC, Graybug Vision, Inc., KalVista Pharmaceuticals, Inc., Kodiak Sciences Inc, Kubota Pharmaceutical Holdings Co. Ltd., Novartis AG, Ocugen Inc., Oculis Holding AG, Ocuphire Pharma, Inc., Oxurion NV, Pfizer Inc., Regeneron Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd., and YD Life Science.

Market Segmentation & Coverage

This research report categorizes the Diabetic Macular Edema Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment
    • Corticosteroid Injections
    • Drugs
    • Laser Treatment
    • Pharmacological Treatment
  • End-User
    • Hospitals
    • Ophthalmology Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Diabetic Macular Edema Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Diabetic Macular Edema Treatment Market?

3. What are the technology trends and regulatory frameworks in the Diabetic Macular Edema Treatment Market?

4. What is the market share of the leading vendors in the Diabetic Macular Edema Treatment Market?

5. Which modes and strategic moves are suitable for entering the Diabetic Macular Edema Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Diabetic Macular Edema Treatment Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising global prevalence of diabetes with increasing geriatric population
      • 5.1.1.2. Increasing awareness of diabetic retinopathy and diabetic macular edema
      • 5.1.1.3. Government-led initiatives to raise awareness about diabetic retinopathy
    • 5.1.2. Restraints
      • 5.1.2.1. High treatment costs of DME treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing introduction of new and advanced treatment options
      • 5.1.3.2. Improved reimbursement policies and healthcare coverage for DME treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Clinical trial design challenges for DME treatments
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Diabetic Macular Edema Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. Corticosteroid Injections
  • 6.3. Drugs
  • 6.4. Laser Treatment
  • 6.5. Pharmacological Treatment

7. Diabetic Macular Edema Treatment Market, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Ophthalmology Clinics

8. Americas Diabetic Macular Edema Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Diabetic Macular Edema Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Diabetic Macular Edema Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. AbbVie Inc.
    • 12.1.2. Adverum Biotechnologies
    • 12.1.3. Aerpio Pharmaceuticals
    • 12.1.4. Alcon Vision LLC
    • 12.1.5. Alimera Sciences, Inc.
    • 12.1.6. Arctic Vision
    • 12.1.7. Bausch & Lomb Incorporated
    • 12.1.8. Chugai Pharmaceutical Co., Ltd.
    • 12.1.9. EyePoint Pharmaceuticals Inc. .
    • 12.1.10. F. Hoffmann-La Roche Ltd.
    • 12.1.11. Genentech, Inc.
    • 12.1.12. GlaxoSmithKline PLC
    • 12.1.13. Graybug Vision, Inc.
    • 12.1.14. KalVista Pharmaceuticals, Inc.
    • 12.1.15. Kodiak Sciences Inc
    • 12.1.16. Kubota Pharmaceutical Holdings Co. Ltd.
    • 12.1.17. Novartis AG
    • 12.1.18. Ocugen Inc.
    • 12.1.19. Oculis Holding AG
    • 12.1.20. Ocuphire Pharma, Inc.
    • 12.1.21. Oxurion NV
    • 12.1.22. Pfizer Inc.
    • 12.1.23. Regeneron Pharmaceuticals Inc
    • 12.1.24. Teva Pharmaceutical Industries Ltd.
    • 12.1.25. YD Life Science
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing